WASHINGTON, D.C. — At New York Comic‑Con on Friday, Blumhouse Productions and its genre label Atomic Monster used a 90‑minute showcase to unveil a slate of horror and thriller projects slated for release through 2025, while downplaying mixed critical response to the recent hit “Other Mommy.”

“Other Mommy” opened to a $120 million domestic gross and $30 million overseas in its first three weeks, surpassing its $12 million production budget by more than tenfold despite a 45 % Rotten Tomatoes rating. Co‑producer James Wan said the controversial title was chosen to “spark conversation and reflect the film’s unsettling mother‑child dynamic,” a decision he believes will sustain long‑term brand equity for Blumhouse.

Actress Kristen Bell confirmed her role in “Violent Night 2,” a sequel slated for a summer 2025 release. Bell, who will portray a re‑imagined Santa figure, said the project “pushes the boundaries of dark comedy while staying true to the franchise’s gritty tone.” The sequel is budgeted at roughly $20 million, a figure the studio expects to recoup through global streaming deals and ancillary markets.

Blumhouse’s upcoming slate includes seven new titles—ranging from a sci‑fi horror anthology to a supernatural thriller—projected to generate $500 million in combined box‑office revenue over the next 18 months. Industry analyst Maya Patel noted that the company’s diversified pipeline “offers investors exposure to multiple revenue streams, from theatrical releases to direct‑to‑digital platforms, mitigating risk associated with any single title.”

Key Takeaways

• “Other Mommy” achieved a 10× return on its production budget despite mixed reviews.
• Kristen Bell joins “Violent Night 2,” which carries a $20 million budget and aims for a summer 2025 launch.
• Blumhouse’s 2024‑2025 slate targets $500 million in revenue, expanding investor appeal through varied distribution channels.

The announcements underscore Blumhouse’s strategy of leveraging high‑impact titles to sustain growth, even as critics remain divided. By coupling bold branding choices with a diversified release schedule, the studio aims to solidify its position in the global horror market and deliver measurable returns for its investors.